<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622841</url>
  </required_header>
  <id_info>
    <org_study_id>NL51405.041.15</org_study_id>
    <nct_id>NCT02622841</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy Followed by Surgical Stabilization for Patients With Unstable Spinal Metastases</brief_title>
  <acronym>BLEND</acronym>
  <official_title>Stereotactic Body Radiotherapy Followed by Surgical Stabilization for Patients With Unstable Spinal Metastases: First-in-Man Study According to the IDEAL Recommendations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the feasibility and safety of combining stereotactic body&#xD;
      radiotherapy (SBRT) and pedicle screw fixation in a 48-hour window for the treatment of&#xD;
      painful unstable metastases of the thoracic and/or lumbar spine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Sixty-five percent of cancer patients with terminal illness have bone metastases,&#xD;
      with debilitating pain as devastating consequence. The spine is the most common location for&#xD;
      bone metastases. Spinal cord compression is present in 10% of patients with vertebral&#xD;
      metastases and aggravates pain and performance status even further. Standard treatment of&#xD;
      unstable vertebral metastases consists of stabilizing surgery, followed by external beam&#xD;
      radiotherapy (8 Gy) after two weeks. Although this approach is effective in 60-70% of&#xD;
      patients, it is has several downsides. Firstly, because of the two weeks interval between&#xD;
      surgery and external beam radiotherapy, necessary for sufficient wound healing, it takes a&#xD;
      long time before radiotherapy induced pain relief is achieved. Scatter artifacts on planning&#xD;
      computed tomography images caused by surgical implants prohibit high-resolution imaging and&#xD;
      accurate targeting of the lesion. Multiple hospital visits (+/- 10) are needed for&#xD;
      administration of external beam irradiation, and in about 30-40% of patients no adequate pain&#xD;
      response is achieved. An alternative treatment strategy, which would lead to faster pain&#xD;
      relief in a higher proportion of patients with less hospital visits, would be highly&#xD;
      desirable from the patient's perspective.&#xD;
&#xD;
      Objective: To assess the feasibility and safety of combining stereotactic body radiotherapy&#xD;
      (SBRT) and pedicle screw fixation in a 48-hour window for the treatment of painful unstable&#xD;
      metastases of the thoracic and/or lumbar spine.&#xD;
&#xD;
      Study design: Prospective case series (13), first in man study, Phase I and II a study&#xD;
      according to the IDEAL recommendations&#xD;
&#xD;
      Study population: All patients, male and female, with impending spinal stability requiring&#xD;
      radiation therapy and surgical intervention at the University Medical Center Utrecht&#xD;
&#xD;
      Main study parameters/endpoints: The main outcome of this study is safety of the combined&#xD;
      procedure, defined as grade 3 or higher treatment-induced toxicity according to common&#xD;
      terminology criteria for adverse events (CTC-AE) 4.0 as a result of the procedure within 60&#xD;
      days after the surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>first 90 days post treatment</time_frame>
    <description>Occurrence of adverse events grade 3/4 according to the common terminology criteria for adverse events (CTCAE) 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain response</measure>
    <time_frame>first 90 days post treatment</time_frame>
    <description>Measurement of pain response to combined therapy according to consensus guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of pain relief</measure>
    <time_frame>first 90 days post treatment</time_frame>
    <description>Measurement of duration of pain relief</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapidity of pain relief</measure>
    <time_frame>first 90 days post treatment</time_frame>
    <description>Measurement of rapidity of pain relief</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>first 90 days post treatment</time_frame>
    <description>Measurement of length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early mortality</measure>
    <time_frame>First 30 days post treatment</time_frame>
    <description>Measurement of 30 days mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological status</measure>
    <time_frame>First 90 days post treatment</time_frame>
    <description>Measurement of neurological deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>first 90 days post treatment</time_frame>
    <description>Evaluation of quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Time from inclusion until date of death from any cause assessed up to 100 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>BLEND</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of stereotactic bodyradiotherapy and surgical stabilization within 48 hours for the treatment of unstable spinal metastases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>BLEND</intervention_name>
    <description>Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.</description>
    <arm_group_label>BLEND</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Painful metastases from solid tumors in the thoracic or lumbar spine needing surgical&#xD;
             stabilization&#xD;
&#xD;
          -  Histologic proof of malignancy&#xD;
&#xD;
          -  Radiographic evidence of spinal metastases&#xD;
&#xD;
          -  Karnofsky performance status â‰¤ 50&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple spinal metastases necessitating bridging more than five vertebral levels&#xD;
             during surgery&#xD;
&#xD;
          -  Previous surgery or radiotherapy to index lesion&#xD;
&#xD;
          -  stereotactic body radiotherapy cannot be delivered (Bilsky score 2 and 3)&#xD;
&#xD;
          -  Neurological deficits (ASIA C, B or A)&#xD;
&#xD;
          -  Partial neurological deficits (ASIA D) with rapid progression (hours to days)&#xD;
&#xD;
          -  Inability to lie flat on table for stereotactic body radiotherapy&#xD;
&#xD;
          -  Non-ambulatory patients&#xD;
&#xD;
          -  Patient in hospice or with &lt; 3 months life expectancy&#xD;
&#xD;
          -  Medically inoperable or patient refused surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorrit-Jan Verlaan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>September 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>J.J. Verlaan</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>First in man</keyword>
  <keyword>Spinal metastases</keyword>
  <keyword>Stereotactic bodyradiotherapy</keyword>
  <keyword>Palliative care</keyword>
  <keyword>Safety</keyword>
  <keyword>Surgical stabilisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

